Insights
Clinical insights for GLP-1 prescribers
Evidence-based guidance on running structured GLP-1 services — from pharmacokinetics to patient retention to regulatory compliance.
What the GPhC Now Expects from GLP-1 Prescribing and Dispensing: A 2026 Compliance Brief
GPhC standards for online weight-loss prescribing have tightened materially since February 2024. Here's the current state of the rules pharmacists, prescribing services and pharmacy owners need to meet — and the inspection patterns that follow them.
OPIP Procurement Readiness: What Pharmacy Buying Groups Need to Lock In Before Summer 2026
The £85M NHS / Eli Lilly Obesity Pathway Innovation Programme runs its first pilots this summer. Buying-group procurement decisions are happening now. Here's what an OPIP-ready wraparound proposition has to demonstrate — and where most current bids fall short.
Behavioural Support for Obesity Prescribing (BSOP): What NICE Requires and How to Deliver It
NICE TA1026 mandates behavioural support alongside every tirzepatide prescription — but the guidance sets expectations, not a programme. Here's a practical implementation guide for prescribers building a BSOP-compliant pathway.
Oral Contraceptive Effectiveness on Tirzepatide: A Prescriber Safety Brief
Tirzepatide reduces peak oral contraceptive concentrations by up to 66% — a clinically significant interaction the MHRA, FDA and FSRH all flag. Semaglutide does not. Here's what prescribers and their patients need to know, and what to say during counselling.
NHS Tirzepatide Rollout: What Community Pharmacies Need to Prepare For
The NHS is rolling tirzepatide out to 220,000 patients over three years with mandatory wraparound support. Here's what that means for community pharmacy — and how to be ready before the referrals start landing.
Food Noise After Stopping GLP-1s: What the Brain Science Shows
Penn Medicine brain imaging reveals why food preoccupation returns after GLP-1 cessation — and what prescribers can do to prepare patients for it.
The Post-Discontinuation Support Gap: An Opportunity for GLP-1 Prescribers
65% of patients stop GLP-1 treatment within a year, yet no competitor offers structured post-treatment support. Here's why that gap is your opportunity.
Restarting GLP-1 Medication: What Prescribers Need to Know About Re-Titration
SmPC restart protocols, gap duration thresholds, drug switching guidance, and a practical checklist for prescribers managing patients who want to resume GLP-1 treatment.
What Happens After Patients Stop GLP-1 Treatment: The Evidence
A comprehensive review of the evidence on weight regain, appetite return, metabolic adaptation, and cardiovascular risk after GLP-1 discontinuation — and why structured support changes outcomes.
Digital Patient Support: The Evidence for Better Adherence
A review of the evidence linking structured digital health interventions to improved medication adherence — and what it means for GLP-1 prescribers.
Nutrition Guidance During GLP-1 Treatment: Evidence-Based Approaches
How to counsel patients on nutrition during GLP-1 treatment — managing reduced appetite, preventing muscle loss, and building sustainable habits.
How Prescribers Can Compete in the GLP-1 Market
The GLP-1 market is growing fast. Here's how independent prescribers can differentiate their service and build a sustainable weight management business.
The First Two Weeks on Mounjaro: What Patients Actually Experience
A week-by-week guide to what patients can expect during their first fortnight on tirzepatide — from injection technique to side effect timelines.
MHRA Registration for Digital Health Tools: What Prescribers Should Know
A guide to MHRA classification, UKCA marking, and what to look for when choosing digital health tools for your GLP-1 service.
Patient-Reported Outcomes: Why Your GLP-1 Service Needs Structured Data
How capturing structured patient-reported outcomes transforms your GLP-1 service from dispensing-only to a data-driven clinical programme.
The Pharmacokinetics of Semaglutide: Why Timing Matters
Understanding semaglutide's absorption, distribution, and elimination — and why pharmacokinetic awareness improves patient counselling.
Building a Weight Management Service: A Practical Guide for Prescribers
How to set up and run a profitable, clinically sound GLP-1 weight management service — whether you're a pharmacy, clinic, or private practice.
Why Patients Drop Off GLP-1 Treatment — And How to Keep Them
GLP-1 dropout rates are high across all prescriber settings. Here's what drives patients away and what structured support can do about it.
Managing GLP-1 Side Effects: What to Tell Your Patients
Practical guidance on managing the most common GLP-1 side effects — nausea, constipation, injection site reactions — and when to escalate.
Semaglutide vs Tirzepatide: Key Differences for Prescribers
A head-to-head comparison of semaglutide and tirzepatide — pharmacology, efficacy data, side effect profiles, and practical prescribing considerations.
What Are GLP-1 Receptor Agonists? A Prescriber's Guide
A clinical overview of GLP-1 receptor agonists — how they work, current approved indications, and what prescribers need to know about semaglutide and tirzepatide.